Overcome Common Pre-Filled Syringe Challenges Through Partnership

The pre-filled syringe (PFS) space is one of the fastest growing pharma sectors, expected to be worth $9.7bn by 2025, or 9% CAGR. Compared with traditional vial delivery systems, PFS offers greater patient safety and lower manufacturing costs – but pre-filled doesn’t translate to easily filled. The increase in biologic drugs – driving the PFS boom – presents particular obstacles, primarily attributed to viscosity.

Your CDMO partner of choice makes a big difference when it comes to pre-filled syringe challenges. In this article, review how to overcome viscosity and controlled processes, better understand how to determine between glass and polymer, and see how to focus on shared risk.